Standard Vape (SVAP) Announces COVID-19 Animal Study and Financing

Animal Testing Facilities Selected for SVAP Nano Nitric Oxide Dry Powder Inhaler as Potential COVID-19 Treatment

LOCUST VALLEY, NY / ACCESSWIRE / July 13, 2020 / Standard Vape Corporation (OTC PINK:SVAP) announced today that its wholly owned subsidiary Neo-Virucide, Inc. (NVI) (www.neovirucide.com) and the Licensor of the NanoNOx™ technology from NMB Therapeutics, Inc.(NMB) have selected Bioneeds India Private Limited, a Good Laboratory Practice (GLP) (FDA compliant) facility in Tumkur, India (www.bioneeds.in) to conduct animal studies of NanoNOxTM a new and innovative approach to delivering Nitric Oxide to COVID-19 patients. Nitric Oxide is approved by the United States Food and Drug Administration (FDA) for use in gas form to treat Hypertension. The NanoNOxTM compound developed by NMB and licensed for worldwide distribution to NVI, the SVAP subsidiary, uses Nano technology to encapsulate Nitric Oxide in a dry powder form that can be inhaled through a conventional inhaler, which will then have a controlled release of nitric oxide deep inside the lungs upon contact with moisture in the lung tissue. We believe that this approach will remove the need for gas tanks, expensive competing technology and provide a portable outpatient friendly treatment approach for mild to moderate COVID-19 cases.

The NMB board deemed progress satisfactory for animal trials, costs of which will be paid by NVI, as a first step to a preIND contact with the FDA. NMB and SVAP would welcome approaches from anyone in the medical or scientific communities who may be able to assist going forward with this new approach. Scientific papers regarding the use of Nano particles and previous studies are available at www.neovirucide.com.

Legal Disclaimer

This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the company and its management team. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. Some or all the events or results anticipated by these forward-looking statements may not occur. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management's control.

Contact Information:

Roger Fidler
NVI President
(201) 220-8734
rfidler0099@aol.com

Brinsley Holman
+44 (0)207 464 4090
brinsley.holman@kbrl.co.uk.

SOURCE: Standard Vape Corp.



View source version on accesswire.com:
https://www.accesswire.com/597049/Standard-Vape-SVAP-Announces-COVID-19-Animal-Study-and-Financing

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.